📊 TECH Key Takeaways
Is BIO-TECHNE Corp (TECH) a Good Investment?
BIO-TECHNE demonstrates solid operational execution with excellent profitability margins (65.7% gross, 19.9% operating), robust free cash flow generation ($176.3M), and an extremely strong balance sheet (0.10x debt-to-equity). However, flat revenue growth (0.0% YoY) and 56.2% EPS decline signal growth stagnation and capital inefficiency, with modest ROE of 6.1% suggesting the company is underdeploying its substantial $2.1B equity base.
BIO-TECHNE Corp Key Strengths (TECH)
- Exceptional gross margins (65.7%) indicating strong competitive moat and pricing power in biological products
- Outstanding free cash flow generation (19.7% FCF margin) demonstrating high-quality, cash-backed earnings
- Fortress balance sheet with minimal leverage (0.10x debt-to-equity), substantial cash reserves ($209.8M), and exceptional liquidity (4.49x current ratio)
- Strong interest coverage (13.4x) reflects low financial distress risk
TECH Stock Risks: BIO-TECHNE Corp Investment Risks
- Revenue stagnation (0.0% YoY growth) raises questions about market saturation, competitive pressure, or product-market fit challenges in biotech sector
- Diluted EPS collapsed 56.2% YoY despite flat net income, indicating significant equity dilution or rising share count
- Weak capital returns (ROE 6.1%, ROA 5.0%) suggest inefficient deployment of $2.1B equity base relative to generating shareholder value
- Lack of growth visibility in a sector historically expected to deliver above-average top-line expansion
Key Metrics to Watch
- Sequential revenue trends and organic growth rate to confirm whether flat growth reflects cyclical pause or structural headwinds
- Share count trajectory and dilution drivers to assess EPS recovery potential independent of earnings
- Return on equity progression as indicator of whether company can improve capital efficiency and justify equity base size
- R&D spending and product pipeline activity to identify future growth catalysts or M&A strategy
BIO-TECHNE Corp (TECH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.49x current ratio provides a solid financial cushion.
TECH Profit Margin, ROE & Profitability Analysis
TECH vs Healthcare Sector: How BIO-TECHNE Corp Compares
How BIO-TECHNE Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BIO-TECHNE Corp Stock Overvalued? TECH Valuation Analysis 2026
Based on fundamental analysis, BIO-TECHNE Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BIO-TECHNE Corp Balance Sheet: TECH Debt, Cash & Liquidity
TECH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BIO-TECHNE Corp's revenue has grown significantly by 31% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.76 reflects profitable operations.
TECH Revenue Growth, EPS Growth & YoY Performance
TECH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $311.4M | $22.6M | $0.14 |
| Q2 2026 | $295.9M | $34.9M | $0.22 |
| Q1 2026 | $286.6M | $33.6M | $0.21 |
| Q3 2025 | $303.4M | $22.6M | $0.14 |
| Q2 2025 | $272.6M | $27.5M | $0.17 |
| Q1 2025 | $276.9M | $33.6M | $0.21 |
| Q3 2024 | $294.1M | $49.1M | $0.31 |
| Q2 2024 | $271.6M | $27.5M | $0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIO-TECHNE Corp Dividends, Buybacks & Capital Allocation
TECH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BIO-TECHNE Corp (CIK: 0000842023)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TECH
What is the AI rating for TECH?
BIO-TECHNE Corp (TECH) has an AI grade of B with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TECH's key strengths?
Claude: Exceptional gross margins (65.7%) indicating strong competitive moat and pricing power in biological products. Outstanding free cash flow generation (19.7% FCF margin) demonstrating high-quality, cash-backed earnings.
What are the risks of investing in TECH?
Claude: Revenue stagnation (0.0% YoY growth) raises questions about market saturation, competitive pressure, or product-market fit challenges in biotech sector. Diluted EPS collapsed 56.2% YoY despite flat net income, indicating significant equity dilution or rising share count.
What is TECH's revenue and growth?
BIO-TECHNE Corp reported revenue of $893.8M.
Does TECH pay dividends?
BIO-TECHNE Corp pays dividends, with $37.4M distributed to shareholders in the trailing twelve months.
Where can I find TECH SEC filings?
Official SEC filings for BIO-TECHNE Corp (CIK: 0000842023) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TECH's EPS?
BIO-TECHNE Corp has a diluted EPS of $0.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TECH's fundamental grade?
Based on our AI fundamental analysis in June 2026, BIO-TECHNE Corp has a B grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TECH stock overvalued or undervalued?
Valuation metrics for TECH: ROE of 6.1% (sector avg: 15%), net margin of 14.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TECH's AI grade for 2026?
Our dual AI analysis gives BIO-TECHNE Corp a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TECH's free cash flow?
BIO-TECHNE Corp's operating cash flow is $196.7M, with capital expenditures of $20.4M. FCF margin is 19.7%.
How does TECH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 14.2% (avg: 12%), ROE 6.1% (avg: 15%), current ratio 4.49 (avg: 2).